Insights › Market reaction

Why Summit Therapeutics (SMMT) Stock Rose 9.84% in 10 Minutes on Nov 16, 2026

The 9.84% gain was larger than any reaction MoveSurge measured after Summit Therapeutics headlines between Aug 18, 2026 and Nov 15, 2026; the largest of those was -0.68% in 10 minutes, on Oct 19, 2026.

Published in ET: Feed time in ET: Approval SMMT +9.84% in 10 min after the headline
  • SMMT rose 9.84% in the 10 minutes after the 04:05:11 ET headline, from $10.47 to $11.50.
  • 172,168 shares changed hands in those 10 minutes.
  • The headline crossed in pre-market trading, 5 hours 25 minutes before the 9:30 ET open.
SMMT Why Summit Therapeutics (SMMT) Stock Rose 9.84% in 10 Minutes on Nov 16, 2026
MoveSurge publish 04:05:11 ET
MoveSurge publish
04:05:11 ET
11.94 11.26 10.55 9.87 11.50 04:03 04:05 04:18
Real 1-minute OHLC candles around publish time. Chart times are New York ET; validated market data captured by MoveSurge.

Reaction by asset (real prices)

Asset2m beforeAt release+1m+10m+1m %+10m %
SMMT 10.47 10.47 10.81 11.50 +3.29% +9.84%

Summit Therapeutics (SMMT) shares rose 9.84% in the 10 minutes after this headline reached the MoveSurge news feed at 04:05:11 ET on Monday, November 16, 2026: “FDA declines approval of Summit Therapeutics' lung cancer drug”

SMMT in the first 10 minutes

From a reference price of $10.47 just before the headline, the stock was up 3.29% after one minute and up 9.84%, at $11.50, after 10 minutes. The move kept building after the first minute. 172,168 shares changed hands in those 10 minutes. The headline crossed in pre-market trading, 5 hours 25 minutes before the 9:30 ET open.

Earlier SMMT headlines and the measured reaction

The 9.84% gain was larger than any reaction MoveSurge measured after Summit Therapeutics headlines between Aug 18, 2026 and Nov 15, 2026; the largest of those was -0.68% in 10 minutes, on Oct 19, 2026.

  1. Oct 23, 2026, 16:37 ET: “Summit Therapeutics and Lunit agree to use AI-powered SCOPE IO pathology analysis to study tumor microenvironments for ivonescimab development” (+0.61% in 10 minutes)
  2. Oct 19, 2026, 07:03 ET: “Summit Therapeutics opens a global Phase II study of ivonescimab-based regimens for advanced clear cell renal cell carcinoma” (-0.68% in 10 minutes)

Summit Therapeutics at a glance

SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
Market value$12.06 billion (as of Nov 16, 2026)

Prices are closes of 1-minute bars. Each move on this page is measured from the last completed bar before its headline.

What headline moved Summit Therapeutics stock on November 16, 2026?

At 04:05:11 ET, this headline crossed: “FDA declines approval of Summit Therapeutics' lung cancer drug”. The stock rose 9.84% in the next 10 minutes.

How far did SMMT move after the headline?

From $10.47 just before the headline to $11.50 10 minutes later, a +9.84% move.

What else has moved SMMT stock recently?

The two largest measured reactions before November 16, 2026: Oct 19, 2026, Summit Therapeutics opens a global Phase II study of ivonescimab-based regimens for advanced clear cell renal cell carcinoma (-0.68% in 10 minutes); Oct 23, 2026, Summit Therapeutics and Lunit agree to use AI-powered SCOPE IO pathology analysis to study tumor microenvironments for ivonescimab development (+0.61% in 10 minutes).

Sources

Follow SMMT live

The live feed pairs breaking headlines with measured price moves. Build a watchlist of stocks you own and choose whether matching news reaches your WhatsApp.

Open the live feed See portfolio WhatsApp alerts
The next market-moving story will not wait

See the important story while it still matters.

Seven market specialists bring experience dating back to 2006. MoveSurge adds the speed, coverage, and clear format built for today’s market.

Core market coverageEquities, macro, currencies and commodities Clear in secondsThe story, source, context, and measured move together Built on evidenceReal headlines, timestamps, prices, and trusted sources
Go real time View the live feed Subscription renews automatically. Cancel before renewal. Information only—no trade calls.